JP6932506B2 - 細胞透過組成物およびそれを用いる方法 - Google Patents

細胞透過組成物およびそれを用いる方法 Download PDF

Info

Publication number
JP6932506B2
JP6932506B2 JP2016534133A JP2016534133A JP6932506B2 JP 6932506 B2 JP6932506 B2 JP 6932506B2 JP 2016534133 A JP2016534133 A JP 2016534133A JP 2016534133 A JP2016534133 A JP 2016534133A JP 6932506 B2 JP6932506 B2 JP 6932506B2
Authority
JP
Japan
Prior art keywords
seq
peptide
transport
cargo moiety
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016534133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500849A5 (enExample
JP2017500849A (ja
Inventor
ウィリアム シー． セッサ
ウィリアム シー． セッサ
フランク ジェイ． ジョルダーノ
フランク ジェイ． ジョルダーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2017500849A publication Critical patent/JP2017500849A/ja
Publication of JP2017500849A5 publication Critical patent/JP2017500849A5/ja
Application granted granted Critical
Publication of JP6932506B2 publication Critical patent/JP6932506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2016534133A 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法 Active JP6932506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908963P 2013-11-26 2013-11-26
US61/908,963 2013-11-26
PCT/US2014/066619 WO2015080943A1 (en) 2013-11-26 2014-11-20 Novel cell-penetrating compositions and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020001263A Division JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Publications (3)

Publication Number Publication Date
JP2017500849A JP2017500849A (ja) 2017-01-12
JP2017500849A5 JP2017500849A5 (enExample) 2017-12-28
JP6932506B2 true JP6932506B2 (ja) 2021-09-08

Family

ID=53199565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534133A Active JP6932506B2 (ja) 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Country Status (5)

Country Link
US (2) US9908915B2 (enExample)
EP (1) EP3074049B1 (enExample)
JP (2) JP6932506B2 (enExample)
ES (1) ES2806027T3 (enExample)
WO (1) WO2015080943A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233055B2 (en) 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
US20230065816A1 (en) * 2020-02-07 2023-03-02 The Reasearch Foundation For Suny Methods for preventing and reversing opioid analgesic tolerance in subjects with chronic pain

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH07507059A (ja) 1992-03-25 1995-08-03 デポムド　システムズ，インコーポレイテッド アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2474807A1 (en) * 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7250398B2 (en) 2003-09-12 2007-07-31 Novozymes A/S Synthetic antimicrobial polypeptides
EP2471809B1 (en) * 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US8309034B2 (en) * 2007-06-09 2012-11-13 Honeywell International Inc. Compositions, methods and devices for control and clean-up of hazardous spills
JP5730578B2 (ja) * 2007-12-21 2015-06-10 フィブロテック セラピューティクス プロプライエタリー リミテッド 抗線維症剤のハロゲン化類似体
EP2250278B1 (en) 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
ES2743622T3 (es) * 2013-11-26 2020-02-20 E & B Tech Llc Tratamiento de la enfermedad autoinmune y/o inflamatoria usando moduladores de la caveolina novedosos

Also Published As

Publication number Publication date
ES2806027T3 (es) 2021-02-16
EP3074049A4 (en) 2017-05-17
US9908915B2 (en) 2018-03-06
US20180201649A1 (en) 2018-07-19
WO2015080943A1 (en) 2015-06-04
EP3074049A1 (en) 2016-10-05
US10550151B2 (en) 2020-02-04
EP3074049B1 (en) 2020-05-06
US20160289269A1 (en) 2016-10-06
JP2017500849A (ja) 2017-01-12
JP2020072716A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
KR101317100B1 (ko) 세포-침투성 펩티드로서 유용한 펩티드
US8242081B2 (en) Cell penetrating peptides for intracellular delivery of molecules
US20100099626A2 (en) Cell penetrating peptides for intracellular delivery of molecules
CN103180340A (zh) 细胞内免疫
JP6692751B2 (ja) 新規カベオリンモジュレーターを使用する自己免疫および／または炎症疾患の治療
JP2018064573A (ja) ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物
JP2020072716A (ja) 細胞透過組成物およびそれを用いる方法
KR101559974B1 (ko) ｓｉＲＮＡ 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
WO2019035919A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING L-PLASTINE ACTIVITY IN OSTEOCLASTES TO REDUCE BONE LOSS
KR101430232B1 (ko) ｓｉＲＮＡ 전달을 위한 ｐ19-ＹＳＡ 재조합 단백질 및 이를 포함하는 조성물
JP7239987B2 (ja) 薬物送達のための抗体融合タンパク質
EP1605964B1 (en) TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
KR20230074753A (ko) 헤지호그 신호전달 경로의 활성화를 위한 강력한 결합제
HK1228790A1 (en) Novel cell-penetrating compositions and methods using same
HK1228790B (en) Novel cell-penetrating compositions and methods using same
KR101595152B1 (ko) Ｔｃｔｐ-ｐｔｄ를 포함하는 유전자 전달체
WO2005017151A1 (ja) アポトーシスを誘導するip3受容体タンパク質の末端切断型変異体
HK1185353A (zh) 细胞内免疫
HK1229701A1 (en) Treatment of inflammatory disease using caveolin linked to an internalisation peptide
HK1229701B (en) Treatment of inflammatory disease using caveolin linked to an internalisation peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200116

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200120

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200306

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200311

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201015

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210524

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210623

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210818

R150 Certificate of patent or registration of utility model

Ref document number: 6932506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250